Article

Percutaneous implantation of the first repositionable aortic valve prosthesis in a patient with severe aortic stenosis

Department of Cardiology, HELIOS Heart Center Siegburg, Siegburg, Germany.
Catheterization and Cardiovascular Interventions (Impact Factor: 2.4). 04/2008; 71(5):579-84. DOI: 10.1002/ccd.21470
Source: PubMed

ABSTRACT Percutaneous aortic valve replacement is a new less-invasive alternative for high-risk surgical candidates with aortic stenosis. However, the clinical experience is still limited, and the currently available 'first-generation devices' revealed technical shortcomings, such as lack of repositionability and presence of paravalvular leakages. We report the first-in-man experience with the new self-expanding Lotus Valve prosthesis composed of a nitinol frame with implemented bovine pericardial leaflets which is designed to address these issues, being repositionable and covered by a flexible membrane to seal paravalvular gaps. We implanted this prosthesis in a 93-year old patient presenting with severe symptomatic aortic stenosis (valve area: 0.6 cm(2)). Surgical valve replacement had been declined due to comorbidities.
We used a retrograde approach for insertion of the 21-French Lotus catheter loaded with the valve prosthesis via surgical cut-down to the external iliac artery. Positioning of the valve was guided by transesophageal echo and supra-aortic angiograms. The prosthesis was successfully inserted and deployed within the calcified native valve. Echocardiography immediately after device deployment showed a significant reduction of the transaortic mean pressure gradient (32 to 9 mmHg; final valve area 1.7 cm(2)) without evidence of residual aortic regurgitation. The postprocedural clinical status improved from NYHA-IV to NYHA-II. These results remained unchanged up to the 3 month follow-up.
Successful percutaneous aortic valve replacement can be performed using the new self-expanding and repositionable Lotus valve for treatment of high-risk patients with aortic valve stenosis. Further studies are mandatory to assess device safety and efficacy in larger patient populations.

0 Followers
 · 
61 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Riassunto La stenosi valvolare aortica rappresenta una importante causa di morbilità e di mortalità. La sua incidenza aumenta con l'aumentare dell'età e la sua prevalenza è in crescita nei paesi industrializzati, soprattutto a causa dell'incremento della spettanza di vita. Per decenni l'intervento di sostituzione valvolare aortica effettuato per via chirurgica (SVA) costituisce il trattamento di scelta per questa patologia. L'esperienza clinica, tuttavia, insegna come numerosi siano i pazienti che, a causa dell'età avanzata o della presenza di gravi co-morbilità, vengono giudicati ad alto rischio chirurgico e pertanto non operabili. I primi ed incoraggianti risultati ottenuti mediante trattamento con valvuloplastica aortica non sono stati suc-cessivamente supportati dalla possibilità di ottenere risultati a lungo termine. I pazienti trattati nella iniziale esperienza del dr. Alan Cribier a Rouen in Francia mostravano comorbilità così severe tali da limitare la aspettativa di vita a lungo termine. La sostituzione della valvola aortica per via percutanea (PAVR) costituisce, allo stato attuale, una nuova e meno invasiva alternativa all'intervento chirurgico per i pazienti ad elevato rischio operatorio con stenosi aortica. L'esperienza clinica di tale procedura è, tuttavia, ancora limitata e "i devices di 1 a generazione" attualmente disponibili presentano ancora molte limitazioni tecniche e procedurali. La principale limitazione è costituita dalla necessità di utilizzare introduttori femorali del diametro di 18 F (59,4 mm) o maggiori. Questo articolo ha lo scopo di presentare quelle che sono le valvole percutanee attualmente utilizzate nella pratica clini-ca, le loro caratteristiche tecniche e le metodiche di impianto. Vengono, inoltre, riportati i risultati dei primi studi clinici, sottolineando i limiti e le possibili complicanze procedurali e quelli che potranno essere i futuri campi di applicazione. Summary Aortic valvular stenosis is a significant cause of morbidity and mortality. Rates increase with age and the prevalence will increase as the population ages. For decades, aortic valve replacement has been the primary treatment for adults with severe aortic stenosis. Clinical experience tells us that a growing number of patients are poor surgical candidates due to advanced age, co-morbidities and previous cardiac surgery. Attempts to offer treatment to these patients with bal-loon aortic valvuloplasty was disappointing, as a durable increase in aortic valve area could not be achieved. Percutaneous aortic valve replacement (PAVR) is a new less-invasive alternative for high-risk surgical candidates with aortic stenosis. However, the clinical experience is still limited, and the currently available 'first-generation devices' revealed technical shortcomings, such as lack the need to utilize femoral introducers with a diameter of 18 F (59.4 mm) or larger. This review explores current percutaneous valve replacement devices and techniques for severe aortic stenosis in high-risk patients, outlines the procedural limits and the complications, discusses some technique-related issues and the future directions.
  • [Show abstract] [Hide abstract]
    ABSTRACT: La implantación percutánea de prótesis valvulares aórticas ha surgido recientemente como alternativa terapéutica en pacientes con estenosis aórtica severa sintomática rechazados para cirugía. Describimos la experiencia inicial con esta técnica en nuestro centro. En 4 pacientes con estenosis aórtica severa sintomática rechazados para cirugía (euroSCORE medio, 23%) se realizó implantación de prótesis valvular aórtica de Edwards-Sapiens por vía transfemoral. En los 4 pacientes, el procedimiento tuvo lugar con éxito, con implantación correcta de la prótesis y sin complicaciones. Al mes de seguimiento, no hubo eventos y todos los pacientes habían mejorado en su clase funcional.
    Revista Espanola de Cardiologia 01/2008; 61(11):1215-1219. DOI:10.1016/S1885-5857(09)60037-2 · 3.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Percutaneous implantation of aortic valve prostheses has recently emerged as a therapeutic option for patients with severe symptomatic aortic stenosis for whom surgical valve replacement is not suitable. We describe our initial experience with this technique at our institution. Percutaneous implantation of an Edwards Sapiens aortic prosthesis was performed using the transfemoral approach in four patients with severe symptomatic aortic stenosis for whom surgery was not suitable (mean EuroSCORE, 23%). The procedure was successful in all patients, with optimal implantation of the prosthesis and no complications. By 1 month of follow-up, no patient had experienced an event and all had improved their functional class.
    Revista Espa de Cardiologia 11/2008; 61(11):1215-1219. DOI:10.1157/13127854 · 3.34 Impact Factor